[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Goeldel AL, Cornillet-Lefebvre P, Durlach A, Birembaut P, Bernard P, Nguyen P, Grange F: T-cell receptor gamma gene rearrangement in cutaneous T-cell lymphoma: comparative study of polymerase chain reaction with denaturing gradient gel electrophoresis and GeneScan analysis. Br J Dermatol; 2010 Apr;162(4):822-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell receptor gamma gene rearrangement in cutaneous T-cell lymphoma: comparative study of polymerase chain reaction with denaturing gradient gel electrophoresis and GeneScan analysis.
  • BACKGROUND: The usefulness of T-cell receptor gene rearrangement (TCR-GR) analyses for differentiating cutaneous T-cell lymphoma (CTCL) from benign inflammatory disorders (BID) has been insufficiently studied to date.
  • OBJECTIVES: To evaluate the diagnostic value of TCR-GR analyses, comparing polymerase chain reaction (PCR) with denaturing gradient gel electrophoresis (DGGE) analysis and BIOMED-2 standardized protocol PCR with GeneScan analysis (BIOMED-2-GS).
  • RESULTS: DGGE and BIOMED-2-GS had a similar diagnostic value for distinguishing CTCL from BID, with a sensitivity of 74% and 77%, respectively, and a specificity of 86%.
  • Positivity rates did not depend on the PCR method but varied according to the type of CTCL (73-75% in mycosis fungoides, 90-100% in Sézary syndrome, 40-60% in lymphomatoid papulosis and 100% in other types).
  • The most frequent BID with a monoclonal pattern were drug-induced cutaneous lymphoid hyperplasia, erythrodermic psoriasis and pityriasis lichenoides chronica.
  • [MeSH-major] Electrophoresis, Polyacrylamide Gel / methods. Gene Rearrangement, T-Lymphocyte / genetics. Lymphoma, T-Cell, Cutaneous / genetics. Polymerase Chain Reaction / methods. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906072.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gels
  •  go-up   go-down


2. Braun RP, French LE, Feldmann R, Chavaz P, Saurat JH: Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules. Br J Dermatol; 2000 Aug;143(2):411-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules.
  • Histological and immunohistochemical findings were suggestive of cutaneous pseudolymphoma (CPL), and extensive screening for malignant lymphoma (ML) remained negative.
  • Cutaneous pseudolymphomas are inflammatory diseases that can simulate ML either clinically, histopathologically, or both.
  • They are a rare cause of nodules of the upper eyelids, usually characterized by a benign evolution, that can be secondary to ultraviolet sensitivity, adverse reactions to systemic medications and contact sensitization, among others.
  • In our case, epicutaneous patch tests were strongly positive for a series of allergens contained in the ophthalmological preparations used; therefore, they were suggestive that the patient had CPL, lymphomatoid contact dermatitis type.
  • In addition, the patient had been treated previously with several drugs, known to cause CPL and immune dysregulation.
  • [MeSH-major] Dermatitis, Allergic Contact / diagnosis. Eyelid Diseases / diagnosis. Pseudolymphoma / diagnosis
  • [MeSH-minor] Aged. Chalazion / drug therapy. Diagnosis, Differential. Female. Humans. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2006 Sep;155(3):633-4 [16911299.001]
  • (PMID = 10951155.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


3. Atalar H, Sarifakioglu E, Dener C, Yanik B, Koktener A, Bayrak R: Cutaneous lymphoid hyperplasia and reactive lymphadenopathy induced by hepatitis B vaccination. Eur J Dermatol; 2008 Mar-Apr;18(2):188-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphoid hyperplasia and reactive lymphadenopathy induced by hepatitis B vaccination.
  • [MeSH-major] Drug Eruptions / diagnosis. Hepatitis B Vaccines / adverse effects. Pseudolymphoma / diagnosis. Vaccination / adverse effects
  • [MeSH-minor] Adult. Arm / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / chemically induced. Hyperplasia / diagnosis. Hyperplasia / pathology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18424381.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


Advertisement
4. Pham-Ledard A, Vergier B, Doutre MS, Beylot-Barry M: Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination. Dermatology; 2010;220(2):176-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination.
  • Vaccine-induced cutaneous lymphoid hyperplasia (CLH) is rare.
  • In this case, occurrence of lesions far from the injection site of the vaccine suggested that it was not the only cause and that CLH may occur in other localizations after a vaccination.
  • [MeSH-major] Hepatitis B Vaccines / adverse effects. Pseudolymphoma / immunology. Skin Neoplasms / immunology. Thalidomide / therapeutic use. Vaccination / adverse effects
  • [MeSH-minor] Adolescent. Antigens, CD3 / immunology. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. Cyclins / therapeutic use. DNA-Binding Proteins / immunology. Female. Humans. Hydroxychloroquine / therapeutic use. Neprilysin / immunology. T-Lymphocytes / drug effects. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029164.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / BCL6 protein, human; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Hepatitis B Vaccines; 4QWG6N8QKH / Hydroxychloroquine; 4Z8R6ORS6L / Thalidomide; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


5. Bachelez H: The uncertain status of cutaneous pseudolymphoma. Actas Dermosifiliogr; 2009 Nov;100 Suppl 1:33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The uncertain status of cutaneous pseudolymphoma.
  • Cutaneous pseudolymphomas (CPLs) include a wide range of clinicopathological presentations sharing in common the presence of clinical and histopathological features mimicking those of primary cutaneous lymphomas.
  • Although immunophenotypical studies and molecular analysis of clonality have been shown to be reliable tools, providing significant help in the differential diagnosis between primary cutaneous lymphoid malignancy and pseudolymphoma involving the skin, the identification of an etiological agent and prolonged follow-up remain the key steps to ascertain the benign, reactive nature of a skin lymphocytic infiltrate.
  • [MeSH-major] Pseudolymphoma / diagnosis. Skin Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096195.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Souteyrand P, d'Incan M, Parent S: [Misleading or rare cutaneous drug reactions]. Rev Prat; 2000 Jun 15;50(12):1329-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Misleading or rare cutaneous drug reactions].
  • Drug hypersensitivity syndrome and drug-induced cutaneous pseudolymphoma were for a long time considered as one and the same.
  • Acute generalized exanthematous pustulosis is a rare drug eruption individualised in 1980.
  • Numerous drugs can induce acneiform eruptions or trigger or even worsen an authentic acne.
  • The number of drugs responsible for buccal mucous membrane involvement is on the increase; gingival hypertrophy remains a rare drug reaction, a certain number of drugs such as nicorandil can cause buccal aphtae and even giant ones.
  • [MeSH-major] Acneiform Eruptions / chemically induced. Drug Eruptions / physiopathology. Drug Hypersensitivity / physiopathology. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10972075.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


7. Stavrianeas NG, Katoulis AC, Bozi E, Toumbis-Ioannou E, Kanelleas AI, Makris M, Kalogeromitros D, Panayiotides I: Cutaneous pseudolymphoma following administration of lornoxicam. Acta Derm Venereol; 2007;87(5):453-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma following administration of lornoxicam.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Piroxicam / analogs & derivatives. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced
  • [MeSH-minor] Adult. Back Pain / drug therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721665.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; ER09126G7A / lornoxicam
  •  go-up   go-down


8. Magro CM, Crowson AN, Kovatich AJ, Burns F: Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol; 2003 Feb;34(2):119-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells.
  • Certain systemic conditions predispose patients to excessive lymphocyte responses to immune-perturbing drugs, which may progress to malignant lymphoma.
  • Many pathologists and clinicians believe that differentiation of pseudolymphoma from cutaneous T cell lymphoma (CTCL) can be reliably made through phenotypic and molecular analysis.
  • We encountered 15 cases of atypical cutaneous T-cell lymphoid hyperplasia in the setting of drug therapy.
  • The lymphoid infiltrates showed reproducible CD7 and/or CD62 K deletion in concert with T cell clonality and variable CD30 positivity-findings similar to those of CTCL-but the rashes resolved or improved substantially after drug modulation.
  • We propose the term "drug-induced reversible lymphoid dyscrasia" to describe this entity.
  • [MeSH-major] Dermatitis / etiology. Pseudolymphoma / chemically induced. Pseudolymphoma / pathology. T-Lymphocytes / pathology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12612879.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


9. Cogrel O, Beylot-Barry M, Vergier B, Dubus P, Doutre MS, Merlio JP, Beylot C: Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol; 2001 Jun;144(6):1235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine.
  • We report a patient with a sodium valproate-induced cutaneous pseudolymphoma, presenting with an erythematous papule, histologically mimicking a non-epidermotropic T-cell lymphoma.
  • Sodium valproate is very rarely responsible for a hypersensitivity syndrome, and our case is the first report of sodium valproate-induced cutaneous pseudolymphoma.
  • The return of the same monoclonal population shows that the recurrence of monoclonal T cells may be observed in benign conditions and is not an exclusive hallmark of cutaneous lymphoma.
  • [MeSH-major] Anticonvulsants / adverse effects. Carbamazepine / adverse effects. Drug Eruptions / etiology. Pseudolymphoma / chemically induced. Valproic Acid / adverse effects

  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11422049.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 33CM23913M / Carbamazepine; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


10. Kim KJ, Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK: CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. Br J Dermatol; 2002 May;146(5):882-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture.
  • Cases of pseudolymphoma induced by intradermal gold injection or gold piercing have previously been described.
  • Most of these cases showed the histopathological finding of B-lymphocyte predominant lymphocytoma cutis.
  • We describe a patient with gold acupuncture-induced T-cell-rich pseudolymphoma.
  • [MeSH-major] Acupuncture Therapy / adverse effects. Drug Eruptions / etiology. Gold / adverse effects. Pseudolymphoma / chemically induced. T-Lymphocyte Subsets / pathology

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000389.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 7440-57-5 / Gold
  •  go-up   go-down


11. Meyer S, Vogt T, Obermann EC, Landthaler M, Karrer S: Cutaneous pseudolymphoma induced by Cimicifuga racemosa. Dermatology; 2007;214(1):94-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma induced by Cimicifuga racemosa.
  • Histologically, the diagnosis of pseudolymphoma (PL) was confirmed.
  • Because of menopausal complaints, the patient had been taking Remifemin(R), a phytotherapeutical agent containing a standardized extract of black cohosh (Cimicifuga racemosa) rhizome for 1 year.
  • Six months after initial administration of this herbal drug, first skin lesions appeared which continuously increased.
  • To the best of our knowledge, this is the first report on cutaneous PL induced by a standardized extract of C. racemosa rhizoma.
  • Thus, though claimed to be poor in adverse effects, the potency of phytotherapeutical agents to induce uncommon cutaneous eruptions needs to be taken into careful reconsideration since the course of cutaneous PL tends to be chronic and indolent if the causative agent is not discontinued.
  • [MeSH-major] Cimicifuga / adverse effects. Plant Extracts / adverse effects. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatology. 2007;214(2):105-7 [17341856.001]
  • (PMID = 17191056.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Remifemin
  •  go-up   go-down


12. Nervi SJ, Schwartz RA: Plasma-cell-predominant B-cell pseudolymphoma. Dermatol Online J; 2008;14(10):12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma-cell-predominant B-cell pseudolymphoma.
  • Clinical and histopathologic findings were most consistent with a diagnosis of cutaneous plasma cell predominant B cell pseudolymphoma.
  • The term cutaneous pseudolymphoma has been coined to describe the accumulation of either T or B cell lymphocytes in the skin that is caused by a nonmalignant stimulus and encompasses several different terms depending on etiology.
  • In cases of cutaneous pseudolymphoma where a cause is identified, treatment entails removing the underlying causative agent.
  • [MeSH-major] B-Lymphocytes / pathology. Facial Dermatoses / diagnosis. Plasma Cells / pathology. Pseudolymphoma / diagnosis. Skin Ulcer / diagnosis
  • [MeSH-minor] Abscess / diagnosis. Dermis / pathology. Diabetes Mellitus, Type 2 / complications. Diagnostic Errors. Eosinophils / pathology. Female. Humans. Keloid / diagnosis. Middle Aged. Pruritus / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061611.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Colli C, Leinweber B, Müllegger R, Chott A, Kerl H, Cerroni L: Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol; 2004 Mar;31(3):232-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases.
  • Lymphocytoma cutis (LC) is considered as the stereotypical example of the cutaneous B-cell pseudolymphomas.
  • It can be induced by various antigenic stimuli including arthropod bites, vaccination, and drugs among others.
  • In endemic regions, Borrelia burgdorferi is the principal causative agent for LC.
  • Histology revealed dense lymphoid infiltrates with prominent germinal centers (GCs) in all cases.
  • [MeSH-major] Borrelia Infections / pathology. Pseudolymphoma / microbiology. Pseudolymphoma / pathology. Skin Diseases / microbiology. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984575.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Bacterial; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


14. Addeo R, Montella L, Baldi A, Cennamo G, Guarrasi R, Faiola V, Caraglia M, Del Prete S: Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma. Clin Colorectal Cancer; 2007 Nov;6(10):728-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma.
  • Some conditions are predisposed to excessive lymphocyte responses, which can progress to a benign condition, ie, atypical cutaneous lymphoid hyperplasia (ACLH), or a malignant lymphoma.
  • Clinical diagnosis of drug-associated pseudolymphoma can be based on a temporal association between drug ingestion and lesion onset followed by resolution without recurrence after discontinuation of drug administration.
  • The authors postulate that chemotherapy can promote an aberrant immune response to an antigen that can be the drug itself or other self-antigens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy. Drug Eruptions / etiology. Lymphatic Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039427.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


15. Bulai-Livideanu C, Michel C, Fricker A, Schubert B, Paul C: [Pseudolymphomatous facial folliculitis in a child: hypochromic appearance]. Ann Dermatol Venereol; 2008 Nov;135(11):765-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The entity called pseudolymphomatous folliculitis (PLF) is a cutaneous pseudolymphoma.
  • DISCUSSION: PLF is defined as a clinical-pathological entity among the cutaneous pseudolymphomas.
  • [MeSH-major] Amoxicillin / therapeutic use. Folliculitis / pathology. Pseudolymphoma / pathology. Skin Diseases / pathology
  • [MeSH-minor] CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / pathology. Child. Dendritic Cells / immunology. Dendritic Cells / pathology. Disease Progression. Humans. Inflammation / pathology. Male

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061657.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 804826J2HU / Amoxicillin
  •  go-up   go-down


16. Saeed SA, Bazza M, Zaman M, Ryatt KS: Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad Med J; 2000 Sep;76(899):577-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A skin biopsy specimen showed a mixed infiltrate of lymphoid cells and eosinophils; many of the lymphocytes were large, pleomorphic, and showed a raised mitotic rate.
  • This apparent cutaneous T cell lymphoma-like reaction is best described as lymphomatoid vascular reaction.
  • The drug induced immune response with an atypical cutaneous lymphoid infiltrate mimics a cutaneous pseudolymphoma.
  • [MeSH-major] Cefuroxime / adverse effects. Cephalosporins / adverse effects. Drug Eruptions / etiology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Pseudolymphoma / diagnosis. Skin Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10964126.001).
  • [ISSN] 0032-5473
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Cephalosporins; O1R9FJ93ED / Cefuroxime
  • [Other-IDs] NLM/ PMC1741723
  •  go-up   go-down


17. Breza TS Jr, Zheng P, Porcu P, Magro CM: Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol; 2006 Jul;33(7):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response.
  • INTRODUCTION: Drugs may be an important cause of atypical lymphocytic infiltration.
  • We report a patient who developed lymphocytoma cutis temporally associated with initiation of fluoxetine therapy that later went on to develop cutaneous marginal zone B-cell lymphoma.
  • The response of peripheral blood lymphocytes to fluoxetine and other drugs was examined in an attempt to ascertain the potential role for drugs in the propagation of these infiltrates.
  • RESULTS: An initial biopsy was consistent with lymphocytoma cutis.
  • Other tested drugs did not have a similar suppressive effect.
  • [MeSH-major] Antidepressive Agents, Second-Generation / adverse effects. Fluoxetine / adverse effects. Lymphoma, B-Cell / chemically induced. Skin Neoplasms / chemically induced
  • [MeSH-minor] Anticonvulsants / pharmacology. Bupropion / pharmacology. Cells, Cultured. Dose-Response Relationship, Drug. Humans. In Situ Hybridization. Lymphocyte Activation / drug effects. Male. Middle Aged. Pseudolymphoma / chemically induced. Pseudolymphoma / pathology. T-Lymphocytes / drug effects. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Bupropion .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872479.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antidepressive Agents, Second-Generation; 01K63SUP8D / Fluoxetine; 01ZG3TPX31 / Bupropion
  •  go-up   go-down


18. Wiesli P, Joos L, Galeazzi RL, Dummer R: Cutaneous pseudolymphoma associated with bromocriptine therapy. Clin Endocrinol (Oxf); 2000 Nov;53(5):656-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma associated with bromocriptine therapy.
  • [MeSH-major] Bromocriptine / adverse effects. Drug Eruptions / etiology. Hormone Antagonists / adverse effects. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106930.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Hormone Antagonists; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


19. Dar NR, Shaheen, Mustafvi SA, Raza N: Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma. J Coll Physicians Surg Pak; 2005 Aug;15(8):496-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma.
  • Cutaneous pseudolymphoma is an aggregate of mature or abnormal looking lymphocytes in the dermis, which clinically and /or histologically simulates lymphoma but has a benign course and outcome.
  • Systemic drugs, especially anti-epileptics, are an important cause of cutaneous pseudolymphomas.
  • Pseudolymphoma of the skin, secondary to topical drug application, is very rare.
  • We report a case of cutaneous pseudolymphoma induced by local application of 4% hydroquinone cream to melasma over the cheeks.
  • [MeSH-major] Hydroquinones / adverse effects. Melanosis / drug therapy. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. HYDROQUINONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202363.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Hydroquinones; 123-31-9 / hydroquinone
  •  go-up   go-down


20. Gilliam AC, Wood GS: Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg; 2000 Jun;19(2):133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphoid hyperplasias.
  • Benign hyperplastic lymphoid infiltrates of the skin (pseudolymphoma, older term) simulate lymphoma clinically and histologically.
  • They can be divided into B-cell predominant (typical cutaneous lymphoid hyperplasia (CLH), angiolymphoid hyperplasia, Kimura's disease, and Castleman's disease) and T-cell predominant (T-cell CLH, lymphomatoid contact dermatitis, and lymphomatoid drug eruption).
  • A composite assessment of clinical presentation and behavior, routine histology, immunophenotyping, and molecular studies is essential for the diagnosis of benign cutaneous lymphoid infiltrates.
  • Treatment depends on the assessment and biologic behavior, which is usually benign.
  • Molecular biologic analysis has shown that a significant proportion of cases harbor occult B- or T-cell clones (clonal CLH).
  • Progression to overt cutaneous lymphoma has been observed in a minority of cases.
  • [MeSH-major] Drug Eruptions / diagnosis. Pseudolymphoma. Skin Diseases

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10892716.001).
  • [ISSN] 1085-5629
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / 1-RO3-AR-45033-01; United States / NIAMS NIH HHS / AR / 1-RO3-AR46423-01; United States / NIAMS NIH HHS / AR / AR39750; etc
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 47
  •  go-up   go-down






Advertisement